LON:DOCS

Dr. Martens (DOCS) Share Forecast, Price & News

GBX 138.60

+0.60 (+0.43%)

(As of 03:51 PM ET)

Compare

Today's Range: 135.30
▼
144.60
50-Day Range: 130.70
▼
171.25
52-Week Range: 127.10
▼
295.21

Volume: 1.07 million shs
Average Volume: 2.31 million shs
Market Capitalization: £1.39 billion

P/E Ratio: 770.00
Dividend Yield: 4.33%
Price Target: GBX 236.67

Profile Analyst Ratings Chart Competitors Dividend Insider Trades Headlines

Dr. Martens MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 68.4% Upside
GBX 236.67 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.40
Based on 12 Articles This Week
Insider Trading: Acquiring Shares
£14,000 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Dr. Martens has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 236.67, Dr. Martens has a forecasted upside of 68.4% from its current price of GBX 140.55.
Amount of Analyst Coverage
Dr. Martens has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for DOCS.

0.8

Dividend Strength

Dividend Yield
Dr. Martens pays a meaningful dividend of 3.50%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dr. Martens does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Dr. Martens is 3,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DOCS.

3.0

News and Social Media Coverage

News Sentiment
Dr. Martens has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.30 average news sentiment score of Consumer Cyclical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Dr. Martens this week, compared to 1 article on an average week.
Search Interest
Only 11 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
1 people have added Dr. Martens to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dr. Martens insiders have bought more of their company's stock than they have sold. Specifically, they have bought £140 in company stock and sold GBX 0 in company stock.
Percentage Held by Insiders
Only 3.86% of the stock of Dr. Martens is held by insiders.
Percentage Held by Institutions
73.32% of the stock of Dr. Martens is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Dr. Martens is 780.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 126.54.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dr. Martens is 780.82, which means that it is trading at a more expensive P/E ratio than the Consumer Cyclical sector average P/E ratio of about 431.99.
Price to Earnings Growth Ratio
Dr. Martens has a PEG Ratio of 0.04. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Dr. Martens has a P/B Ratio of 4.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dr. Martens (LON:DOCS) Stock

Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

Receive DOCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Martens and its competitors with MarketBeat's FREE daily newsletter.

DOCS Stock News Headlines

June 1, 2023 | thetimes.co.uk

Docs smarting at profit margins

June 1, 2023 | americanbankingnews.com

Dr. Martens plc (LON:DOCS) Declares Dividend of GBX 4.28

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

June 1, 2023 | msn.com

Bootmaker Dr Martens' annual profit slumps as demand wanes

June 1, 2023 | nasdaq.com

Bootmaker Dr Martens flags hit to profit margins on higher investments

June 1, 2023 | finance.yahoo.com

Dr Martens tripped up by tough U.S. market

June 1, 2023 | finance.yahoo.com

UPDATE 1-Bootmaker Dr Martens flags hit to profit margins on higher investments

June 1, 2023 | finance.yahoo.com

Dr Martens warns profit margins set to fall this year

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 31, 2023 | msn.com

These Dr. Martens boots have been a celebrity favorite for a decade

May 30, 2023 | americanbankingnews.com

Dr. Martens (LON:DOCS) Downgraded to "Sector Perform" at Royal Bank of Canada

May 23, 2023 | msn.com

Dr Martens sandals hurting your feet? Experts share how to break them in

May 22, 2023 | msn.com

Lucky thrifter scores ‘rare’ pair of Dr. Martens for a fraction of the price: ‘I’m hunting these on eBay right now’

May 15, 2023 | yahoo.com

This New Yorker loves to pair an over-the-top lace skirt with chunky Dr. Martens

May 10, 2023 | yahoo.com

Dr. Martens Hits on Grunge Gold With the Jadon Boot

April 14, 2023 | nasdaq.com

UK bootmaker Dr Martens warns of lower profit as costs rise; CFO resigns

April 14, 2023 | msn.com

Bootmaker Dr Martens warns on profit as finance chief walks

April 14, 2023 | reuters.com

UK bootmaker Dr Martens warns of lower profit as costs rise

April 14, 2023 | msn.com

Dr.Martens says warehouse headache led to disappointing revenue rise as hunt for new CFO begins

April 13, 2023 | yahoo.com

Dr. Martens x Original Shift Document Industry Gamechangers With Limited-Edition Zine

April 10, 2023 | msn.com

Next shoppers applaud 'classic and comfortable' £38 Spring sandals that look like £99 Dr Martens

March 30, 2023 | msn.com

Shoppers share 'genius hack' to get money off Uggs, Dr. Martens & more

March 29, 2023 | msn.com

Luciana Barroso’s Sexy LBD Is the Perfect Complement to Husband Matt Damon’s Doc Martens

March 28, 2023 | nz.finance.yahoo.com

The 12 Best Ankle Boots of 2023 To Wear Everywhere

March 28, 2023 | americanbankingnews.com

Dr. Martens (LON:DOCS) Sets New 1-Year Low at $127.50

March 27, 2023 | msn.com

Dr. Martens is having a super rare sale — we’ve never seen them this cheap!

March 25, 2023 | msn.com

Shopper shares how they nabbed a pair of ‘fresh,’ like-new Doc Martens for just $15: ‘Never thought I’d see the day’

See More Headlines

DOCS Price History

30 days | 90 days | 365 days | Advanced Chart

DOCS Company Calendar

Today: 6/02/2023
Ex-Dividend for 7/18 Dividend: 6/08/2023
Dividend Payable: 7/18/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Footwear & Accessories
Sub-Industry: N/A
Sector: Consumer Cyclical
Current Symbol: LON:DOCS
CUSIP: N/A
CIK: N/A
Web: www.drmartensplc.com
Phone: 44 12 1415 7047
Fax: N/A
Employees: 1,897
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 236.67
High Stock Price Forecast: GBX 350
Low Stock Price Forecast: GBX 180
Forecasted Upside/Downside: +64.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 0.18
Trailing P/E Ratio: 798.89
Forward P/E Ratio: 0.14
P/E Growth: 0.04
Net Income: £177.30 million
Net Margins: 18.53%
Pretax Margin: N/A
Return on Equity: 64.46%
Return on Assets: 16.34%

Debt

Debt-to-Equity Ratio: 125.74
Current Ratio: 2.39
Quick Ratio: 1.13

Sales & Book Value

Annual Sales: £957 million
Price / Sales: 1.50
Cash Flow: GBX 10.07 per share
Price / Cash Flow: 14.29
Book Value: GBX 35 per share
Price / Book: 4.11

Miscellaneous

Outstanding Shares: 1,000,000,000
Free Float: N/A
Market Cap: £1.44 billion
Optionable: Not Optionable
Beta: 0.08

Key Executives

Mr. Kenneth Wilson (Age 56)
CEO & Director
Comp: $750k

Mr. Jon W. Mortimore
CFO & Director

Mr. Geert Peeters (Age 57)
Chief Operating Officer

Mr. Ronald Garricks
Chief Information Officer

Ms. Emily Reichwald
Gen. Counsel & Company Sec.

Ms. Meg Johnson
Chief Marketing Officer

Ms. Sue Gannon
Chief HR Officer

Mr. Lorenzo Moretti
Pres of EMEA

Mr. Sean O'Neill
Chief Digital Officer

Mr. Derek Chan
Pres of APAC

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

DOCS Stock - Frequently Asked Questions

Should I buy or sell Dr. Martens stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Martens in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DOCS shares.
View DOCS analyst ratings or view top-rated stocks.
What is Dr. Martens' stock price forecast for 2023?: 3 Wall Street analysts have issued 1 year price targets for Dr. Martens' shares. Their DOCS share price forecasts range from GBX 180 to GBX 350. On average, they anticipate the company's stock price to reach GBX 236.67 in the next year. This suggests a possible upside of 64.6% from the stock's current price.
View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts.
How have DOCS shares performed in 2023?: Dr. Martens' stock was trading at GBX 190.60 at the beginning of the year. Since then, DOCS shares have decreased by 24.6% and is now trading at GBX 143.80.
View the best growth stocks for 2023 here.
How often does Dr. Martens pay dividends? What is the dividend yield for Dr. Martens?: Dr. Martens declared a dividend on Thursday, June 1st. Shareholders of record on Thursday, June 8th will be paid a dividend of GBX 4.28 per share on Tuesday, July 18th. This represents a yield of 2.74%. The ex-dividend date is Thursday, June 8th. This is a positive change from the stock's previous dividend of GBX 1.56. The official announcement can be accessed at this link.
Read our dividend analysis for DOCS.
Is Dr. Martens a good dividend stock?: Dr. Martens (LON:DOCS) pays an annual dividend of GBX 6 per share and currently has a dividend yield of 3.50%. The dividend payout ratio is 3,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for DOCS.

What is Dr. Martens' stock symbol?: Dr. Martens trades on the London Stock Exchange (LON) under the ticker symbol "DOCS."
How do I buy shares of Dr. Martens?: Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Dr. Martens' stock price today?: One share of DOCS stock can currently be purchased for approximately GBX 143.80.
How much money does Dr. Martens make?: Dr. Martens (LON:DOCS) has a market capitalization of £1.44 billion and generates £957 million in revenue each year. The company earns £177.30 million in net income (profit) each year or GBX 0.18 on an earnings per share basis.
How many employees does Dr. Martens have?: The company employs 1,897 workers across the globe.
How can I contact Dr. Martens?: The official website for the company is www.drmartensplc.com. The company can be reached via phone at 44 12 1415 7047.

This page (LON:DOCS) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dr. Martens (DOCS) Share Forecast, Price & News

Dr. Martens MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Dr. Martens (LON:DOCS) Stock

DOCS Stock News Headlines

DOCS Price History

DOCS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

DOCS Stock - Frequently Asked Questions

Overall MarketRank^™